Insider Selling: Repare Therapeutics Inc. (NASDAQ:RPTX) CEO Sells 2,650 Shares of Stock

Repare Therapeutics Inc. (NASDAQ:RPTX) CEO Lloyd Mitchell Segal sold 2,650 shares of the firm’s stock in a transaction on Wednesday, March 27th. The stock was sold at an average price of $4.63, for a total value of $12,269.50. Following the completion of the sale, the chief executive officer now directly owns 83,866 shares of the company’s stock, valued at $388,299.58. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

Lloyd Mitchell Segal also recently made the following trade(s):

• On Monday, March 25th, Lloyd Mitchell Segal sold 2,650 shares of Repare Therapeutics stock. The stock was sold at an average price of $4.79, for a total value of $12,693.50.

Repare Therapeutics Trading Up 3.1 %

Shares of RPTX opened at $4.67 on Thursday. The firm has a market cap of $172.79 million, a P/E ratio of -2.09 and a beta of 0.62. The company’s 50-day moving average price is $6.33 and its 200 day moving average price is $6.60. Repare Therapeutics Inc. has a 12-month low of $3.08 and a 12-month high of $13.85.

Repare Therapeutics (NASDAQ:RPTX) last issued its quarterly earnings results on Wednesday, February 28th. The company reported ($0.67) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.56) by ($0.11). The business had revenue of $13.05 million for the quarter, compared to analysts’ expectations of $15.92 million. Repare Therapeutics had a negative return on equity of 39.82% and a negative net margin of 183.43%. Equities research analysts forecast that Repare Therapeutics Inc. will post -2.74 earnings per share for the current year.

Institutional Trading of Repare Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of RPTX. Barclays PLC purchased a new stake in Repare Therapeutics during the second quarter worth about $36,000. Deutsche Bank AG purchased a new stake in Repare Therapeutics during the fourth quarter worth about $40,000. UBS Group AG increased its stake in Repare Therapeutics by 26.3% during the third quarter. UBS Group AG now owns 3,551 shares of the company’s stock worth $43,000 after purchasing an additional 739 shares during the period. Wells Fargo & Company MN increased its stake in shares of Repare Therapeutics by 185.8% during the fourth quarter. Wells Fargo & Company MN now owns 3,041 shares of the company’s stock worth $45,000 after buying an additional 1,977 shares during the period. Finally, SRS Capital Advisors Inc. purchased a new stake in shares of Repare Therapeutics during the first quarter worth approximately $49,000. 85.09% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of analysts have issued reports on RPTX shares. HC Wainwright reaffirmed a “buy” rating and issued a $10.00 target price on shares of Repare Therapeutics in a research note on Wednesday, February 21st. Bloom Burton lowered shares of Repare Therapeutics from a “buy” rating to an “accumulate” rating in a report on Tuesday, February 13th.

Repare Therapeutics Company Profile

Repare Therapeutics Inc, a clinical-stage precision oncology company, engages in the discovery and development of therapeutics by using its synthetic lethality approach in Canada and the United States. It uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform, to discover, validate, and build a pipeline of SL-based therapeutics that focuses on genomic instability, including DNA damage repair.